CN1125049C - 托拉沙得新晶体变型n - Google Patents
托拉沙得新晶体变型n Download PDFInfo
- Publication number
- CN1125049C CN1125049C CN99811710A CN99811710A CN1125049C CN 1125049 C CN1125049 C CN 1125049C CN 99811710 A CN99811710 A CN 99811710A CN 99811710 A CN99811710 A CN 99811710A CN 1125049 C CN1125049 C CN 1125049C
- Authority
- CN
- China
- Prior art keywords
- torsaemide
- crystal modifications
- acid
- new crystal
- crystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 131
- 238000012986 modification Methods 0.000 title claims abstract description 113
- 230000004048 modification Effects 0.000 title claims abstract description 113
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 title abstract 6
- 229960005461 torasemide Drugs 0.000 title abstract 6
- 238000000034 method Methods 0.000 claims abstract description 31
- 238000002360 preparation method Methods 0.000 claims abstract description 21
- 150000007524 organic acids Chemical class 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 19
- 238000002050 diffraction method Methods 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 14
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 11
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 8
- 239000003637 basic solution Substances 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- 230000036770 blood supply Effects 0.000 claims description 6
- 206010006451 bronchitis Diseases 0.000 claims description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 125000006850 spacer group Chemical group 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 5
- 239000011707 mineral Substances 0.000 claims description 5
- 235000010755 mineral Nutrition 0.000 claims description 5
- 239000011541 reaction mixture Substances 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 239000000428 dust Substances 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- 235000017550 sodium carbonate Nutrition 0.000 claims description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 4
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 208000007333 Brain Concussion Diseases 0.000 claims description 3
- 206010048962 Brain oedema Diseases 0.000 claims description 3
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 3
- 206010010904 Convulsion Diseases 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- 206010014418 Electrolyte imbalance Diseases 0.000 claims description 3
- 208000010412 Glaucoma Diseases 0.000 claims description 3
- 206010020571 Hyperaldosteronism Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 3
- 206010030113 Oedema Diseases 0.000 claims description 3
- 206010037423 Pulmonary oedema Diseases 0.000 claims description 3
- 208000007536 Thrombosis Diseases 0.000 claims description 3
- 206010052428 Wound Diseases 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 208000006752 brain edema Diseases 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 208000007451 chronic bronchitis Diseases 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 239000002934 diuretic Substances 0.000 claims description 3
- 230000001882 diuretic effect Effects 0.000 claims description 3
- 210000005003 heart tissue Anatomy 0.000 claims description 3
- 230000004410 intraocular pressure Effects 0.000 claims description 3
- 230000004060 metabolic process Effects 0.000 claims description 3
- 229910017604 nitric acid Inorganic materials 0.000 claims description 3
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims description 3
- 235000019260 propionic acid Nutrition 0.000 claims description 3
- 208000005333 pulmonary edema Diseases 0.000 claims description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 3
- 238000012546 transfer Methods 0.000 claims description 3
- 230000009466 transformation Effects 0.000 claims description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
- 238000002441 X-ray diffraction Methods 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 238000010586 diagram Methods 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 235000006408 oxalic acid Nutrition 0.000 claims description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 2
- 235000015320 potassium carbonate Nutrition 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 239000012670 alkaline solution Substances 0.000 abstract 1
- 238000012512 characterization method Methods 0.000 abstract 1
- 150000007522 mineralic acids Chemical class 0.000 abstract 1
- 235000005985 organic acids Nutrition 0.000 abstract 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 238000000634 powder X-ray diffraction Methods 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 238000001291 vacuum drying Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000003643 water by type Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000012530 fluid Substances 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 101000607872 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 21 Proteins 0.000 description 4
- 102100039918 Ubiquitin carboxyl-terminal hydrolase 21 Human genes 0.000 description 4
- 239000008119 colloidal silica Substances 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 2
- 208000012904 Bartter disease Diseases 0.000 description 2
- 208000010062 Bartter syndrome Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 2
- 229960005017 olanzapine Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229960001203 stavudine Drugs 0.000 description 2
- MZLSCEPYBSMALM-UHFFFAOYSA-N CC(C)NOC(=O)NS(=O)(=O)C=1C=NC=CC1NC1=CC(=CC=C1)C Chemical compound CC(C)NOC(=O)NS(=O)(=O)C=1C=NC=CC1NC1=CC(=CC=C1)C MZLSCEPYBSMALM-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000012822 chemical development Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000012362 drug development process Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000008863 intramolecular interaction Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/53—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Liquid Crystal (AREA)
- Liquid Crystal Substances (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及托拉沙得新晶体变型N的特征,涉及在添加或不添加晶种的情况下,通过用无机酸或有机酸受控制地酸化碱性托拉沙得溶液来制备托拉沙得新晶体变型N的方法,及其用作制备托拉沙得晶体变型I和药用托拉沙得盐的原料,以及涉及含这种托拉沙得新晶体变型N的药物形态。
Description
技术领域
本发明涉及N-(1-甲基乙基氨基羰基)-4-(3-甲基-苯基氨基)-3-吡啶磺酰胺(本文中称为“托拉沙得新晶体变型),本发明尤其涉及托拉沙得新晶体变型N及其制备方法,及其作为制备托拉沙得晶体变型I和作为制备药用托拉沙得盐的原料,以及包含作为活性成分的所述托拉沙得新晶体变型N的药物形态。
背景技术
拉托沙得是一种具有药理性质的化合物,已公开在德国专利2516025(实施例71)中。作为亨勒襻的利尿剂,它可用作防止心脏或心脏组织受到因与局部供血不足有关的新陈代谢或电解质紊乱而引起的损伤的药剂,可用来治疗血栓形成、心绞痛、气喘、高血压、肾水肿、肺水肿、一级和二级醛甾酮过多症、Bartter氏综合症、肿瘤、青光眼、使眼压下降、急性或慢性支气管炎、还可用来治疗因外伤引起的大脑水肿、局部供血不足、脑震荡、转移或癫痫发作以及治疗因变态反应引起的鼻部感染。
一种物质能以一种以上晶体形态存在的现象称为同质多晶现象,这些不同晶型称为“多晶变型”或“多晶型物”。一般来说,同质多晶现象受物质分子改变构型的可能性或形成不同分子间的作用或分子内相互作用的可能性的影响,尤其是受氢键的影响,同质多晶现象反映出不同多晶型物的晶格中的不同的原子排列。已经发现了几种有机化合物呈同质多晶现象。药物中有约70%巴比妥酸盐、60%磺酰胺和60%甾族化合物已发现有同质多晶现象,而且市场上有约50%所述种类的药物不是以它们最稳定的形态销售的(T.Laird,“精细化学工业中的化学进展及演化、原理和实践教程”(Chemical Development and Scale-up in the Fine ChemicalIndustry,Principles and Practices,Course Manual)”,Scientific Update,Wyvern Cattage,1996)。
物质的不同多晶型物具有不同的晶格能量,因此,在固态时它们显示出不同的物理性质(如形态、密度、熔点、颜色、稳定性、溶解速率、研磨可能性、成粒作用、压紧性等),在药剂中这些性质会影响各种药物形态的制备、稳定性、溶解性和生物利用度,从而影响药物的作用。
因为一种有关同质多晶现象的完整知识是阐明整个药物研制过程的关键观察结果的先决条件,因此,药物的同质多晶现象是学科专家们研究的课题[J.Haleblian,W.McCrone,“制药科学杂志(J.Pharm.Sci.)”58(1969)911;L.Borka,(Pharm.Acta Helv.)66(1991)16;M.Kuhnert-Brandsttter,“药物学(Pharmazie)”51(1996)443;H.G.Brittain.“制药科学杂志(J.Pharm.Sci)”86(1997)405;W.H.Streng,DDT 2(1997)415;K.Yoshii,“化学制药公报(Chem.Pham.Bull.)”45(1997)338,等]。于是,在决定药物以固体状态及有关剂量大小、稳定性、溶解作用和预期的作用进行生产时,必须确定所有存在的固体形态(在市场上可找到一些计算机程序,例如作为《Cerius 2》程序的模块《Polymorph》,MSI Inc.,USA),以及确定每种固体形态的稳定性、溶解作用以及热力学性质。只有在确定这些因素的基础上才能为药物配方的研制选出适用的晶型。
现从大量的研究工作中只选出几项研究作介绍。Gordon等人的美国专利4476248保护了一种布洛芬新晶型及其制备方法;Bunnell等人的欧洲专利733635保护了一种奥氮平新晶型及其制备方法以及含这种新晶型药物奥氮平的药物配方;R.B.Gandhi等人的欧洲专利749969保护了从stavudine I、II和III形态的混合物中制备stavudine多晶型I的新方法;A.Caron等人的欧洲专利708103保护了一种依具沙坦新晶型及其制备方法以及含该晶型的药物配方。
众所周知[如从晶体学学报(Acta Cryst.)B34(1978),2659-2662和“晶体学学报(Acta Cryst.)”B34(1978),1304-1310可知]托拉沙得可呈两种具有不同单晶胞参数的晶体变型,这已由单晶的X射线衍射实验得到证实。通过缓慢蒸发出托拉沙得在石油醚/乙醇混合物中的溶液的溶剂,在除去溶剂时可同时形成两种晶体变型。晶体变型I的熔点为169℃,呈P 21/c(棱晶)空间群的单斜晶型,而晶体变型II的熔点为162℃,呈P 2/n(薄片)空间群的单斜晶型。此外,Iyakuhin Kenkyu25(1994),734-750中对晶体变型I熔点为169.22℃作了说明。
根据德国专利2516025中的实施例71,得到的托拉沙得是熔点为163-164℃的晶型。
在美国专利4743693和美国再颁专利34580或美国专利4822807和美国再颁专利34672中,公开了通过向托拉沙得的不稳定变型在水中的悬浮体添加催化量(1%)托拉沙得的稳定变型I,并在室温至90℃搅拌混合物3小时至14天,而由托拉沙得的不稳定变型II制成托拉沙得的稳定变型I的方法。美国专利4743693和美国再颁专利34580公开的托拉沙得的稳定变型I(单斜、P 21/c空间群)的熔点为162℃,托拉沙得的不稳定变型II(单斜,P 2/n空间群)的熔点为169℃,这一结果与“晶体学学报(Acta Cryst.)”B34(1978),2659-2662,“晶体学学报(ActaCryst.)”B34(1978)1304-1310和Iyakuhin Kenkyu 25(1994),734-750中所述结果相反。
在美国专利4822807的摘要中,作者们确定托拉沙得的稳定多晶型物I的熔点为162℃,托拉沙得的不稳定多晶型物II的熔点为169℃,而所述专利的权利要求项中说明的每一种多晶型物的熔点与此不同,即多晶型物I的熔点为169℃而多晶型物II的熔点为162℃。
在美国再颁专利34672的摘要中,作者们确定纯的托拉沙得变型I的熔点为162℃,托拉沙得变型II的熔点为169℃,而权利要求项中纯的多晶型物I的熔点为159-161.5℃,不稳定的多晶型物II的熔点为约157.5-约160℃。
发明内容
已经出乎意料地发现,在0-35℃温度下,在添加或不添加晶种的情况下,通过用无机酸或有机酸在15分钟-25小时内受控制地酸化托拉沙得碱性溶液可制得托拉沙得新晶体变型N。
根据本发明方法的托拉沙得碱性溶液是指托拉沙得合成的初始反应混合物的碱性提取液,任何一种托拉沙得晶体变型I、II或N的碱性溶液或任何一种托拉沙得晶体变型I、II或N的相互混合物的碱性溶液。
在本发明方法中,可采用氢氧化锂、氢氧化钠和氢氧化钾的水溶液以及碳酸钠和碳酸钾的水溶液来制备托拉沙得变型的碱性溶液。
可用无机酸如盐酸、硫酸、磷酸和硝酸以及用有机酸如甲酸、乙酸、丙酸、草酸、酒石酸、甲磺酸和对甲苯磺酸来酸化本发明的托拉沙得碱性溶液。
作为本发明方法中的晶种,可采用一种同结构物质的晶体粉末,特别是托拉沙得晶体变型N的晶体粉末。
还业已发现,采用本发明方法托拉沙得不会发生分解,通过本发明方法,可能存在于托拉沙得合成的初始反应混合物的碱性萃取液中或存在于托拉沙得变型I、II或N中的杂质会进入碱中,即可得到化学纯的托拉沙得晶体变型N。
此外,还业已发现,托拉沙得新晶体变型N在通常贮存条件和高湿度条件下是稳定的,这就意味着,它既不会转变成托拉沙得的不稳定变型II,也不会转变成托拉沙得的稳定变型I。
托拉沙得新晶体变型N的特征X射线粉末衍射图是由PHILIPS PW3710衍射仪以Cu X-射线[λ(CuKα1)=1.54046和λ(Cukα2)=1.54439]对托拉沙得新晶体变型N的粉末试样作X衍射测定得到的。于是得到的晶格面间的特征间距(以《d》表示;单位为埃)以及与之相对应的特征相对强度(以《I/I0》表示,%)的结果列于表1中。表1
变型N | |
d() | I/I0(%) |
15.3898 | 2.8 |
12.5973 | 5.4 |
11.4565 | 5.8 |
9.7973 | 69.8 |
9.5493 | 76.6 |
8.6802 | 28.5 |
8.2371 | 100.0 |
7.6351 | 10.2 |
7.3356 | 13.0 |
6.9759 | 1.2 |
6.5351 | 10.0 |
6.3240 | 7.9 |
6.1985 | 4.5 |
5.9521 | 0.6 |
5.6237 | 24.4 |
5.5623 | 29.7 |
5.4040 | 19.6 |
5.1119 | 10.3 |
4.8738 | 22.7 |
4.7865 | 46.9 |
4.6986 | 45.7 |
4.5985 | 17.9 |
4.4602 | 24.7 |
4.3405 | 90.0 |
4.2552 | 20.7 |
4.1829 | 19.9 |
4.0768 | 19.9 |
3.9377 | 47.1 |
3.8659 | 29.3 |
3.8429 | 35.3 |
3.7801 | 42.8 |
3.7248 | 11.9 |
3.6239 | 31.7 |
3.5556 | 20.5 |
3.4825 | 7.8 |
3.4130 | 8.1 |
3.3055 | 15.5 |
3.2298 | 8.2 |
3.1786 | 10.7 |
3.1278 | 5.6 |
3.0699 | 7.1 |
3.0078 | 17.5 |
2.9549 | 5.1 |
2.9056 | 4.3 |
2.8541 | 1.8 |
2.7686 | 13.9 |
2.6988 | 5.7 |
2.6610 | 6.3 |
2.6293 | 7.3 |
2.5549 | 3.7 |
2.5236 | 2.0 |
2.4485 | 5.3 |
2.4161 | 6.7 |
2.3671 | 2.0 |
2.3133 | 3.6 |
2.2788 | 7.6 |
2.2312 | 3.4 |
2.1852 | 6.2 |
2.1468 | 3.0 |
2.0957 | 4.7 |
2.0617 | 4.1 |
2.0273 | 3.3 |
1.9896 | 3.1 |
1.9688 | 4.1 |
1.9274 | 2.6 |
1.8853 | 2.7 |
1.7931 | 2.1 |
1.7449 | 1.0 |
1.7169 | 1.8 |
1.6512 | 1.0 |
1.6122 | 0.8 |
1.5601 | 0.8 |
1.5320 | 0.3 |
1.5057 | 0.5 |
1.4521 | 0.3 |
1.3773 | 0.6 |
此外,借助四圆PHILIPS PW 1100/Stoe&Cie衍射仪的Mo X-射线[λ(moKα=0.71073]记录托拉沙得新晶体变型N单晶衍射,将得到的单晶胞基本结晶学数据与托拉沙得晶型I和II的文献数据[“晶体学学报(Acta Cryst.)”B34(1978),2659-2662和“晶体学学报(ActaCryst.)”B34(1978)1304-1310]作比较,结果显示,该晶型完全是托拉沙得的一种新晶体变型N。
托拉沙得晶体变型I、II和新晶体变型N的基本结晶学数据(单晶衍射)列于表2中。表2
参数 | 托拉沙得的晶体变型 | ||
I | II | N | |
晶体结构 | 单斜晶系 | 单斜晶系 | 单斜晶系 |
空间群 | P 21/c | P 2/n | P 21/c |
a() | 13.308 | 20.446 | 11.430 |
b() | 8.223 | 11.615 | 19.090 |
c() | 31.970 | 16.877 | 16.695 |
β(°) | 107.01 | 108.90 | 93.903 |
V(3) | 3345.5 | 3791.9 | 3634.7 |
Z | 4×2 | 4×2 | 4×2 |
根据本发明方法制备的托拉沙得新晶体变型N可通过常规方法转变为托拉沙得晶体变型I,即它可用作制备已知的托拉沙得晶体变型I的原料。
根据本发明制备的托拉沙得新晶体变型N可通过常规方法转变成药用托拉沙得盐。
托拉沙得新晶体变型N在水中和人工肠液中的溶解特性(USP23)与托拉沙得的已知晶体变型I和II在相同液体中的溶解特性作比较,结果显示,有明显的差别。
托拉沙得新晶体变型N在人工胃液中的IDR(固有溶解速率)超过1毫克/(平方厘米·分钟),由此可说明该晶型具有相当好的生物利用度。
根据本发明方法制备的托拉沙得新晶体变型N具有棱晶特性,呈可流动的晶体粉末状,这种晶型具有流动性,即处于“自由流动”形态,其中不会发生静电荷积聚。
根据本发明方法制备的托拉沙得新晶型N可用作利尿剂以及可用作防止心脏或心脏组织受到因与局部供血不足有关的新陈代谢或电解质紊乱而引起的损伤的药剂,可用来治疗血栓形成、心绞痛、气喘、高血压、肾水肿、肺水肿、一级和二级醛甾酮过多症、Bartter氏综合症、肿瘤、青光眼、使眼压下降、急性或慢性支气管炎、还可用来治疗因外伤引起的大脑水肿、局部供血不足、脑震荡、转移或癫痫发作以及治疗因变态反应引起的鼻部感染。
本发明还涉及药物形态,例如包含作为活性成分的、与药用的一种或多种药用添加剂如糖、淀粉、淀粉衍生物、纤维素、纤维素衍生物、脱模剂以及防粘剂和流动性调节剂相混合的托拉沙得新晶型N的片剂。当采用托拉沙得新晶型N来制备各种形态的药物时,也可采用以水处理如用水粒化的步骤。
用于本发明方法的起始物料,即托拉沙得合成的初始反应混合物的碱性提取液可按照德国专利2516025制备,而托拉沙得变型I和II可按照“晶体学学报(Acta Cryst.)”B34(1978),1304-1310制备。
附图说明
图1显示托拉沙得在水中的溶解试验曲线;
图2显示托拉沙得在人工肠液中的溶解试验曲线。
具体实施方式
下面将通过实施例对本发明作说明。
实施例1
技术上纯净的托拉沙得新晶型N:
按照德国专利2516025制备的托拉沙得合成的反应混合物的初始碱性提取液(1000毫升),在添加1.4克托拉沙得晶体变型N的情况下以10%乙酸水溶液酸化。在室温下搅拌该悬浮液90分钟。经吸滤分离出晶体,以1升软化水洗涤,然后在50℃的真空干燥箱中干燥3小时。可得到125克熔点为162-165℃的托拉沙得晶体变型N。
所得晶体试样的X-射线粉末衍射图与托拉沙得新晶体变型N相符。按照高压液相色谱法(HPLC)测得的托拉沙得含量>99%。
实施例2
将按照实施例1制得的托拉沙得晶体变型N(1000克)溶于10倍量的5%氢氧化钾水溶液中,并于20℃,在添加10克托拉沙得晶体变型N的情况下,用5%盐酸水溶液酸化所得溶液。在20℃下搅拌该悬浮液120分钟。经吸滤分离出晶体,以4升软化水洗涤之,然后在50℃的真空干燥箱中干燥3小时。得到961克熔点为165℃的托拉沙得变型N。
所得晶体试样的X-射线粉末衍射图与托拉沙得晶体变型N相符,按照HPLC方法测得的托拉沙得含量>99.5%,即相当于化学纯托拉沙得。
实施例3
将按照“晶体学学报(Acta Cryst.)”B34(1978),1304-1310制得的托拉沙得晶体变型I(1.00克)溶于10倍量的10%碳酸钠水溶液中,并于15℃、在添加0.10克托拉沙得变型N的情况下,用5%硫酸水溶液酸化所得溶液。在15℃下搅拌该悬浮液120分钟。经吸滤分离出晶体,以4毫升软化水洗涤之,然后在50℃的真空干燥箱中干燥3小时。得到0.95克熔点为165-166℃的托拉沙得晶体变型N。
所得晶体试样的X-射线粉末衍射图与托拉沙得晶体变型N相符。按照HPLC方法测得的托拉沙得含量>99.5%,即相当于化学纯托拉沙得。
实施例4
将按照“晶体学学报(Acta Cryst.)”B34(1978),1304-1310制得的托拉沙得晶体变型II(1.00克)溶于10倍量的10%碳酸钾水溶液中,然后于15℃、在添加0.10克托拉沙得变型N的情况下,用5%硝酸水溶液酸化所得溶液。在15℃下搅拌该悬浮液120分钟。经吸滤分离出晶体,以4毫升软化水洗涤之,然后在50℃的真空干燥箱中干燥3小时。得到0.96克熔点为164-166℃的托拉沙得晶体变型N。
所得晶体试样的X-射线粉末衍射图与托拉沙得晶体变型N相符。按照HPLC方法测得的托拉沙得含量>99.5%,即相当于化学纯托拉沙得。
实施例5
将按照“晶体学学报(Acta Cryst.)”B34(1978),1304-1310制备的托拉沙得晶体变型I和II的混合物溶于10倍量的10%氢氧化锂水溶液中,然后于室温、在添加0.10克托拉沙得变型N的情况下,用5%磷酸水溶液酸化所得溶液。在15℃下搅拌该悬浮液240分钟。经吸滤分离出晶体,以4毫升软化水洗涤之,然后在50℃的真空干燥箱中干燥3小时。得到0.97克熔点为165-166℃的托拉沙得晶体变型N。
所得晶体试样的X-射线粉末衍射图与托拉沙得晶体变型N相符。按照HPLC方法测得的托拉沙得含量>99.5%,即相当于化学纯托拉沙得。
实施例6
将分别按照“晶体学学报(Acta Cryst.)”B34(1978),1304-1310和实施例1制得的托拉沙得晶体变型I和N的混合物(1.00克)溶于10倍量的5%氢氧化钾水溶液中,然后于30℃、在添加0.10克托拉沙得变型N的情况下,用10%酒石酸水溶液酸化所得溶液。在30℃下搅拌该悬浮液180分钟。经吸滤分离出晶体,以4毫升软化水洗涤之,然后在50℃的真空干燥箱中干燥3小时。得到0.93克熔点为164-166℃的托拉沙得晶体变型N。
所得晶体试样的X-射线粉末衍射图与托拉沙得晶体变型N相符。按照HPLC方法测得的托拉沙得含量>99.5%,即相当于化学纯托拉沙得。
实施例7
将分别按照“晶体学学报(Acta Cryst.)”B34(1978),1304-1310和实施例1制得的托拉沙得晶体变型II和N的混合物(1.00克)溶于10倍量的5%氢氧化钠水溶液中,然后于35℃、在添加0.10克托拉沙得变型N的情况下,用5%丙酸水溶液酸化所得溶液。在35℃下搅拌该悬浮液90分钟。经吸滤分离出晶体,用4毫升软化水洗涤之,然后在50℃的真空干燥箱中干燥3小时。得到0.87克熔点为165℃的托拉沙得晶体变型N。
所得晶体试样的X-射线粉末衍射图与托拉沙得晶体变型N相符。按照HPLC方法测得的托拉沙得含量>99.5%,即相当于化学纯托拉沙得。
实施例8
将按照“晶体学学报(Acta Cryst.)”B34(1978),1304-1310和实施例1制得的托拉沙得晶体变型I、II和N的混合物(1.00克)溶于10倍量的10%碳酸钠水溶液中,然后于25℃、在添加0.10克托拉沙得变型N的情况下,用5%对甲苯磺酸水溶液酸化所得溶液。在25℃下搅拌该悬浮液60分钟。经吸滤分离出晶体,用4毫升软化水洗涤之,并在50℃的真空干燥箱中干燥3小时。得到0.93克熔点为164-166℃的托拉沙得晶体变型N。
所得晶体试样的X-射线粉末衍射图与托拉沙得晶体变型N相符。按照HPLC方法测得的托拉沙得含量>99.5%,即相当于化学纯托拉沙得。
实施例9
将按“晶体学学报(Acta Cryst.)”B34(1978),1304-1310制得的托拉沙得晶体变型I(1.00克)溶于10倍量的10%碳酸钾水溶液中,然后在15℃,用10%乙酸水溶液逐步酸化所得溶液,与此同时逐步使混合物温度降至0℃,在该温度下搅拌该悬浮液25小时。经吸滤分离出晶体,用4毫升软化水洗涤之,然后在50℃真空干燥箱中干燥3小时。得到0.94克熔点为164-166℃的托拉沙得晶体变型N。
所得晶体试样的X-射线粉末衍射图与托拉沙得晶体变型N相符。按照HPLC方法测得的托拉沙得含量>99.5%,即相当于化学纯托拉沙得。
实施例10
2.5毫克片剂的制备:
以常规方法使托拉沙得晶体变型N与乳糖和玉米淀粉相混合,然后用水粒化,并干燥和过筛(粒料1)。将胶态二氧化硅与硬脂酸镁相混合、过筛并混入粒料1中。然后以常规方法将混合物压成片。对于生产100000片片剂所需的物料如下:
托拉沙得晶体变型N 0.25千克
乳糖(Lactose Extra Fine Crystal HMS) 6.05千克
玉米淀粉(Starch) 1.60千克
胶态二氧化硅(Aerosil200) 60.00克
硬脂酸镁 40.00克
重蒸馏水 1.20千克
实施例11
100毫克片剂的制备:
以常规方法使托拉沙得晶体变型N与乳糖和玉米淀粉及一部分硬脂酸镁相混合。对该混合物进行挤压并过筛以达到所要求的粒度和粒度分布(粒料1)。使胶态二氧化硅与硬脂酸镁相混合、过筛,并混入粒料1中。然后以常规方法将混合物压成片。对于生产100000片片剂所需的物料如下:
托拉沙得晶体变型N 10.0千克
乳糖(Lactose Extra Fine Crystal HMS) 2.0千克
玉米淀粉(Stareh) 7.7千克
胶态二氧化硅(Aerosil200) 0.2千克
硬脂酸镁 0.1千克
实施例12
将按照“晶体学学报(Acta Cryst.)”B34(1978),1304-1310和实施例1制得的托拉沙得的微晶变型I、II和N置于37℃的水中和人工肠液中进行溶解试验(USP23),试验结果列于表3和表4中。表3:托拉沙得在水中的溶解试验(USP23)(37℃,50rpm,1000毫升)
表4:托拉沙得在人工肠液中的溶解试验(USP23)(37℃,50rpm,pH7.5,
分钟 | %溶解托拉沙得 | ||
变型I | 变型II | 变型N | |
0 | 0 | 0 | 0 |
10 | 6.7 | 15.1 | 15.6 |
20 | 13.0 | 27.8 | 28.1 |
30 | 18.5 | 39.2 | 37.7 |
40 | 23.5 | 48.8 | 43.6 |
50 | 28.5 | 56.3 | 48.5 |
60 | 32.8 | 65.1 | 51.1 |
1000毫升)
分钟 | %溶解托拉沙得 | ||
变型I | 变型II | 变型N | |
0 | 0 | 0 | 0 |
10 | 29.4 | 73.3 | 41.0 |
20 | 40.5 | 92.6 | 59.8 |
30 | 48.4 | 95.5 | 70.2 |
40 | 54.2 | 96.8 | 77.6 |
50 | 59.2 | 96.3 | 82.5 |
60 | 65.0 | 98.2 | 88.7 |
表3所列数据已绘成曲线,见图1。表4所列数据已绘成曲线,见图2。
Claims (16)
1.托拉沙得新晶体变型N,其特征在于由PHILIPS PW3710衍射仪以Cu X-射线[λ(CuKα1)=1.54046埃和λ(CuKα2)=1.54439埃]测得的其试样的特征X-射线粉末衍射图是以下列晶格面之间的间距表示的:
托拉沙得新晶体变型N
d()
15.3898
12.5973
11.4565
9.7973
9.5493
8.6802
8.2371
7.6351
7.3356
6.9759
6.5351
6.3240
6.1985
5.9521
5.6237
5.5623
5.4040
5.1119
4.8738
4.7865
4.6986
4.5985
4.4602
4.3405
4.2552
4.1829
4.0768
3.9377
3.8659
3.8429
3.7801
3.7248
3.6239
3.5556
3.4825
3.4130
3.3055
3.2298
3.1786
3.1278
3.0699
3.0078
2.9549
2.9056
2.8541
2.7686
2.6988
2.6610
2.6293
2.5549
2.5236
2.4485
2.4161
2.3671
2.3133
2.2788
2.2312
2.1852
2.1468
2.0957
2.0617
2.0273
1.9896
1.9688
1.9274
1.8853
1.7931
1.7449
1.7169
1.6512
1.6122
1.5601
1.5320
1.5057
1.4521
1.3773
并且根据四圆PHILIPS PW1100/Stoe & Cie衍射仪以Mo X-射线[λ(MoKα)=0.71073埃]测得的其试样单晶体的X-射线衍射,所述托拉沙得新晶体变型N是以下列基本结晶学数据表示的:
参数
托拉沙得的新晶体变型
晶体结构
单斜晶系
空间群
P 21/c
a()
11.430
b()
19.090
c()
16.695
β(°)
93.903
V(3)
3634.7
Z
4×2
2.根据权利要求1的托拉沙得新晶体变型N,其特征在于它是化学纯的。
3.根据权利要求1或2的托拉沙得新晶体变型N,其特征在于它不含水。
4.根据权利要求1或2的托拉沙得新晶体变型N,其特征在于它不含溶剂。
5.制备根据权利要求1的托拉沙得新晶体变型N的方法,其特征在于碱性托拉沙得溶液于0-35℃、在添加或不添加晶种的情况下,以无机酸或有机酸在15分钟-25小时内受控制地酸化。
6.根据权利要求5的托拉沙得新晶体变型N的制备方法,其特征在于采用托拉沙得合成的初始反应混合物的碱性提取液作为碱性托拉沙得溶液。
7.根据权利要求5的托拉沙得新晶体变型N的制备方法,其特征在于采用任何一种托拉沙得晶体变型I、II或N的碱性溶液,或采用任何一种托拉沙得晶体变型I、II或N的相互混合物的碱性溶液作为碱性托拉沙得溶液。
8.根据权利要求5-7任一项的方法,其特征在于采用氢氧化锂、氢氧化钠、氢氧化钾、碳酸钠或碳酸钾的水溶液来制备碱性托拉沙得溶液。
9.根据权利要求5-7任一项的方法,其特征在于采用无机酸或者是有机酸来实施酸化。
10.根据权利要求9的方法,其中所述无机酸是盐酸、硫酸、磷酸或硝酸而所述有机酸是甲酸、乙酸、丙酸、草酸、酒石酸、甲磺酸或对甲苯磺酸。
11.根据权利要求5-7任一项的方法,其特征在于采用托拉沙得晶体变型N的晶体粉末作为晶种。
12.根据权利要求1的托拉沙得新晶体变型N,其特征在于它用作制备托拉沙得晶体变型I的原料。
13.根据权利要求1的托拉沙得新晶体变型N,其特征在于它用作制备药用托拉沙得盐的原料。
14.根据权利要求1的托拉沙得新晶体变型N的用途,用于制备利尿剂;防止心脏或心脏组织受到因与局部供血不足有关的新陈代谢或电解质紊乱而引起的损伤的药剂;用来治疗血栓形成、心绞痛、气喘、高血压、肾水肿、肺水肿、一级和二级醛甾酮过多症、Batter氏综合症、肿瘤、青光眼、使眼压下降、急性或慢性支气管炎的药物;以及用来治疗因外伤引起的大脑水肿、局部供血不足、脑震荡、转移或癫痫发作以及治疗因变态反应引起的鼻部发炎的药物。
15.一种药物组合物,其特征在于该药物包含作为活性成分的、与药用的一种或多种载体、添加剂或稀释剂相混合的根据权利要求1的托拉沙得晶体变型N。
16.根据权利要求15的药物组合物,其特征在于它是片剂。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HRP980532A | 1998-10-02 | ||
HR980532A HRP980532B1 (en) | 1998-10-02 | 1998-10-02 | Novel crystalline torasemide modification |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1321149A CN1321149A (zh) | 2001-11-07 |
CN1125049C true CN1125049C (zh) | 2003-10-22 |
Family
ID=10946825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN99811710A Expired - Fee Related CN1125049C (zh) | 1998-10-02 | 1999-10-01 | 托拉沙得新晶体变型n |
Country Status (32)
Country | Link |
---|---|
US (5) | US6399637B1 (zh) |
EP (1) | EP1117643B1 (zh) |
JP (1) | JP2002526532A (zh) |
KR (1) | KR100437307B1 (zh) |
CN (1) | CN1125049C (zh) |
AT (1) | ATE286024T1 (zh) |
AU (1) | AU759291B2 (zh) |
BG (1) | BG105485A (zh) |
BR (1) | BR9915018A (zh) |
CA (1) | CA2345789A1 (zh) |
CZ (1) | CZ20011031A3 (zh) |
DE (2) | DE69922977C5 (zh) |
DK (1) | DK1117643T3 (zh) |
EE (1) | EE04341B1 (zh) |
ES (1) | ES2237158T3 (zh) |
HK (1) | HK1040250B (zh) |
HR (1) | HRP980532B1 (zh) |
HU (1) | HUP0104009A3 (zh) |
ID (1) | ID29931A (zh) |
IL (1) | IL142150A0 (zh) |
NO (1) | NO317107B1 (zh) |
NZ (1) | NZ510898A (zh) |
PL (1) | PL346975A1 (zh) |
PT (1) | PT1117643E (zh) |
RU (1) | RU2210569C2 (zh) |
SI (1) | SI1117643T1 (zh) |
SK (1) | SK4232001A3 (zh) |
TR (1) | TR200100909T2 (zh) |
UA (1) | UA72895C2 (zh) |
WO (1) | WO2000020395A1 (zh) |
YU (1) | YU24001A (zh) |
ZA (1) | ZA200102451B (zh) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6394707B1 (en) | 1997-05-08 | 2002-05-28 | Jack Kennedy Metal Products & Buildings, Inc. | Yieldable mine roof support |
HRP980532B1 (en) | 1998-10-02 | 2005-06-30 | Pliva | Novel crystalline torasemide modification |
MXPA02001369A (es) | 1999-08-11 | 2005-08-26 | Teva Pharma | Torasemidas polimorfas. |
DE10013289A1 (de) * | 2000-03-17 | 2001-09-20 | Knoll Ag | Torasemid enthaltende pharmazeutische Zubereitungen |
HRP20000162B1 (en) * | 2000-03-20 | 2004-06-30 | Pliva D D | Amorphous torasemide modification |
HRP20000328A2 (en) * | 2000-05-19 | 2002-02-28 | Pliva Farmaceutska Ind Dionik | Novel polymorph v of torasemide |
IN192178B (zh) * | 2001-08-03 | 2004-03-06 | Ranbaxy Lab | |
HRP20020603B1 (en) * | 2002-07-19 | 2008-11-30 | Pliva D.D. | New process for the preparation of modification i n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridinesulfonamide |
CA2424644A1 (en) * | 2003-04-07 | 2004-10-07 | David John Mckenzie | Preparation of torasemide |
US20050065183A1 (en) * | 2003-07-31 | 2005-03-24 | Indranil Nandi | Fexofenadine composition and process for preparing |
PL1750862T3 (pl) * | 2004-06-04 | 2011-06-30 | Teva Pharma | Kompozycja farmaceutyczna zawierająca irbesartan |
JP4406845B2 (ja) | 2007-02-20 | 2010-02-03 | トヨタ自動車株式会社 | 二次電池電極材の剥離剤及び該剥離剤を用いた二次電池の処理方法 |
EP2705843A1 (en) * | 2012-09-05 | 2014-03-12 | Pharnext | Therapeutic approaches for treating epilepsy and related disorders through reduction of epileptogenesis |
CN104370805B (zh) * | 2013-08-13 | 2016-09-07 | 天津汉瑞药业有限公司 | 托拉塞米化合物 |
CN106038500A (zh) * | 2016-05-26 | 2016-10-26 | 南京正科医药股份有限公司 | 一种托拉塞米片 |
CN115417810B (zh) * | 2022-09-22 | 2023-10-10 | 南京正科医药股份有限公司 | 一种托拉塞米晶型ⅰ的精制方法 |
CN117486789A (zh) * | 2023-12-29 | 2024-02-02 | 江西中医药大学 | 一种托拉塞米共晶盐及其制备方法和应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4055650A (en) * | 1974-04-17 | 1977-10-25 | A. Christiaens Societe Anonyme | Certain 4-phenoxy(or phenylthio)-3-n-acylated-sulfonamido-pyridines |
GB1477664A (en) * | 1974-04-17 | 1977-06-22 | Christiaens Sa A | Pyridine derivatives |
US4473693A (en) | 1978-08-04 | 1984-09-25 | Stewart Walter W | Aminonaphthalimide dyes for intracellular labelling |
DE3529529A1 (de) * | 1985-08-17 | 1987-02-19 | Boehringer Mannheim Gmbh | Verfahren zur herstellung einer stabilen modifikation von torasemid |
US6166041A (en) * | 1995-10-11 | 2000-12-26 | Euro-Celtique, S.A. | 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma |
HRP980532B1 (en) | 1998-10-02 | 2005-06-30 | Pliva | Novel crystalline torasemide modification |
US6166045A (en) * | 1998-06-02 | 2000-12-26 | Roche Diagnostics Gmbh | Torasemide of modification III |
US5914336A (en) * | 1998-06-02 | 1999-06-22 | Boehringer Mannheim Gmbh | Method of controlling the serum solubility of orally administered torasemide and composition relating thereto |
-
1998
- 1998-10-02 HR HR980532A patent/HRP980532B1/xx not_active IP Right Cessation
-
1999
- 1999-10-01 SI SI9930744T patent/SI1117643T1/xx unknown
- 1999-10-01 PL PL99346975A patent/PL346975A1/xx not_active Application Discontinuation
- 1999-10-01 CN CN99811710A patent/CN1125049C/zh not_active Expired - Fee Related
- 1999-10-01 DE DE69922977T patent/DE69922977C5/de not_active Revoked
- 1999-10-01 NZ NZ510898A patent/NZ510898A/xx unknown
- 1999-10-01 KR KR10-2001-7004079A patent/KR100437307B1/ko not_active IP Right Cessation
- 1999-10-01 WO PCT/HR1999/000023 patent/WO2000020395A1/en active IP Right Grant
- 1999-10-01 PT PT99949272T patent/PT1117643E/pt unknown
- 1999-10-01 ES ES99949272T patent/ES2237158T3/es not_active Expired - Lifetime
- 1999-10-01 ZA ZA200102451A patent/ZA200102451B/en unknown
- 1999-10-01 DE DE29924789U patent/DE29924789U1/de not_active Expired - Lifetime
- 1999-10-01 HU HU0104009A patent/HUP0104009A3/hu unknown
- 1999-10-01 JP JP2000574512A patent/JP2002526532A/ja active Pending
- 1999-10-01 AU AU62240/99A patent/AU759291B2/en not_active Ceased
- 1999-10-01 RU RU2001111831/04A patent/RU2210569C2/ru not_active IP Right Cessation
- 1999-10-01 CZ CZ20011031A patent/CZ20011031A3/cs unknown
- 1999-10-01 EP EP99949272A patent/EP1117643B1/en not_active Revoked
- 1999-10-01 SK SK423-2001A patent/SK4232001A3/sk not_active Application Discontinuation
- 1999-10-01 DK DK99949272T patent/DK1117643T3/da active
- 1999-10-01 CA CA002345789A patent/CA2345789A1/en not_active Abandoned
- 1999-10-01 EE EEP200100194A patent/EE04341B1/xx not_active IP Right Cessation
- 1999-10-01 BR BR9915018-2A patent/BR9915018A/pt not_active IP Right Cessation
- 1999-10-01 ID IDW20010958A patent/ID29931A/id unknown
- 1999-10-01 TR TR2001/00909T patent/TR200100909T2/xx unknown
- 1999-10-01 UA UA2001031966A patent/UA72895C2/uk unknown
- 1999-10-01 AT AT99949272T patent/ATE286024T1/de not_active IP Right Cessation
- 1999-10-01 YU YU24001A patent/YU24001A/sh unknown
- 1999-10-01 IL IL14215099A patent/IL142150A0/xx unknown
- 1999-11-05 US US09/434,439 patent/US6399637B1/en not_active Expired - Fee Related
-
2001
- 2001-03-30 NO NO20011633A patent/NO317107B1/no unknown
- 2001-05-02 BG BG105485A patent/BG105485A/xx unknown
-
2002
- 2002-03-13 US US10/096,277 patent/US6833379B2/en not_active Expired - Fee Related
- 2002-03-15 HK HK02102011.9A patent/HK1040250B/zh not_active IP Right Cessation
-
2004
- 2004-06-21 US US10/871,667 patent/US20040229919A1/en not_active Abandoned
-
2006
- 2006-02-21 US US11/357,109 patent/US20060205951A1/en not_active Abandoned
-
2007
- 2007-07-03 US US11/822,274 patent/US20070276015A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1125049C (zh) | 托拉沙得新晶体变型n | |
CN105769792A (zh) | 含1-(β-D-吡喃葡糖基)-3-(苯基噻吩基甲基)苯化合物的片剂 | |
JP2007161734A (ja) | S−オメプラゾールの新規な形態 | |
JP2016509031A (ja) | トレラグリプチンの固形形式及びその製造方法と用途 | |
RU2613555C2 (ru) | Моногидратный кристалл калиевой соли фимасартана, способ его получения и содержащая его фармакологическая композиция | |
CN102639531A (zh) | 噻托溴铵的无水合物 | |
CN103570621B (zh) | 一种(-)-石杉碱甲的制备 | |
JPH0576945B2 (zh) | ||
CN103664881A (zh) | 结晶变体形态b的达比加群酯及其制备方法和用途 | |
CN103224467A (zh) | 一种(-)-石杉碱甲的制备方法 | |
EP1801110A1 (en) | Esomeprazole arginine salt | |
CN104045615A (zh) | (1s)-1-[4-氯-3-(4-乙氧基苄基)苯基]-1,6-二脱氧-d-葡萄糖的晶型a及其制备方法和应用 | |
CN1211368C (zh) | 无定形的托拉塞米变体 | |
CN1520403A (zh) | 托拉塞米的新颖多晶型物v | |
CN114671839B (zh) | 达格列净的固体形式复合物及其制备方法与应用 | |
MX2007011967A (es) | Un proceso mejorado para la fabricacion de rabeprazol sodico. | |
JPH06504541A (ja) | 4−アミノ−3−アシルキノリン誘導体の塩およびその胃酸分泌抑制剤としての使用 | |
EP1942100A1 (en) | Amorphous and crystalline forms of rivastigmine hydrogentartrate | |
KR101896062B1 (ko) | 무정형 리나글립틴의 제조 방법 | |
CN103864756B (zh) | 丁二磺酸达比加群酯及其制备方法和用途 | |
KR20200099016A (ko) | 모사프리드시트르산염수화물의 제조방법 및 이를 포함하는 약학제제 | |
CN112791085A (zh) | 一种替米沙坦制剂中间体的制备方法 | |
CN110684026A (zh) | 一种利格列汀的工业化制备方法 | |
CN104781240A (zh) | 同位素富集的芳基磺酰胺ccr3拮抗剂 | |
KR101804207B1 (ko) | 무정형 리나글립틴의 제조 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |